Introduction: Liver disease mortality in the UK has risen by more than 400% since 19701, in contrast to other common chronic diseases such as heart
hepatoSIGHT® is a case-finding system that helps clinical teams use routine historical data to identify people who may have undiagnosed progressive liver disease and could benefit from further assessment.
Recruitment to liver disease clinical trials remains one of the biggest barriers to progress.
Despite the growing burden of liver disease and the large number of studies, finding eligible participants remains a major challenge. But why?
Bristol, UK | 30 June 2026 – Bristol NHS Group has begun using a new digital tool to help find people who may be at risk
27 May 2026, Somerset, UK and Barcelona, Spain: Predictive Health Intelligence today announced results from the LiveWell study at the EASL Congress, demonstrating that hepatoSIGHT
Royal Cornwall Hospitals NHS Trust launch major new programme for preventive care. Truro, UK, 12 May 2026: Royal Cornwall Hospitals NHS Trust (RCHT) has begun using
Liver disease is one of the clearest examples of health inequality within the UK. Unlike many other major diseases, liver-related mortality continues to rise, with
When Jane received a letter about her liver health, she admits she was surprised – but pleasantly so. Living in rural Somerset and working 30
When the letter from the NHS dropped through my door, I’ll be honest – I didn’t panic. These days, my wife and I joke that
Somerset, UK, 18th March 2026: Predictive Health Intelligence (PHI) and Sano Genetics today announced the completion of recruitment into the LiveWell study, with 996 participants
This website uses cookies to enhance your experience. Please click accept to continue or, Click Here to find out more information.